immunotherapy improves PFS and OS in TNBC
Interviews and expert commentary tagged “immunotherapy improves PFS and OS in TNBC” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among
31 October 2018
6 mins